11. FRI0494 Secukinumab provides rapid and sustained pain relief in psoriatic arthritis: 2-year results from the future 2 study. (15th June 2017) Authors: McInnes, IB; Mease, PJ; Schett, G; Kirkham, B; Strand, V; Williams, N; Fox, T; Pricop, L; Jugl, S; Gandhi, KK Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 675 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study. (15th June 2017) Authors: Nash, P; Coates, LC; Kivitz, AJ; Mease, PJ; Gladman, DD; Covarrubias-Cobos, JA; Fleishaker, D; Wang, C; Kudlacz, E; Menon, S; Hendrikx, T; Kanik, KS Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. FRI0510 Correlation of the routine assessment of patient index data (RAPID-3) with other psoriatic arthritis composite disease activity measures in patients receiving adalimumab. (15th June 2017) Authors: Mease, PJ; Chen, S; Ganz, F; Tillett, W Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. FRI0511 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. (15th June 2017) Authors: Mease, PJ; McInnes, IB; Reich, K; Nash, P; Andersson, M; Abrams, K; Pricorp, L; Fox, T Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. FRI0512 Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (156-week) improvements in basdai in psoriatic arthritis patients: pooled results from 3 phase iii, randomized, controlled trials. (15th June 2017) Authors: Mease, PJ; Marzo-Ortega, H; Poder, A; Bosch, F Van den; Wollenhaupt, J; Lespessailles, E; McIlraith, M; Teng, L; Hall, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. FRI0513 Long-term (156 weeks) improvements in physical function of dmard-naÏve and dmard/biologic-experienced psoriatic arthritis patients treated with apremilast: data from a large database of 4 phase iii clinical trials. (15th June 2017) Authors: Mease, PJ; Wells, A; Wollenhaupt, J; Hall, S; Bosch, F Van den; Lespessailles, E; McIlraith, M; Nguyen, D; Teng, L; Edwards, CJ Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 684 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. (15th June 2017) Authors: Mease, PJ; Hall, S; FitzGerald, O; Heijde, D van der; Merola, JF; Avila-Zapata, F; Cieślak, D; Graham, D; Wang, C; Menon, S; Hendrikx, T; Kanik, KS Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2. (15th June 2017) Authors: McInnes, IB; Mease, PJ; Ritchlin, C; Rahman, P; Gottlieb, A; Kirkham, B; Kajekar, R; Delicha, EM; Pricop, L; Mpofu, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trial. (15th June 2017) Authors: Kavanaugh, A; Gladman, DD; Gomez-Reino, JJ; Hall, S; Lespessailles, E; Mease, PJ; Schett, G; McIlraith, M; Delev, N; Paris, M; Teng, L; Wollenhaupt, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 936 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. SAT0448 Apremilast treatment and long-term (up to 156 weeks) improvements in dactylitis and enthesitis in patients with psoriatic arthritis: analysis of a large database of the phase iii clinical development program. (15th June 2017) Authors: Gladman, DD; Kavanaugh, A; Gomez-Reino, JJ; Wollenhaupt, J; Cutolo, M; Schett, G; Lespessailles, E; McIlraith, M; Hu, C; Edwards, CJ; Birbara, CA; Mease, PJ Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗